News roundup

Inaphaea news round-up: March 2024 

This news round-up covers our updates from March. BioEurope was a key highlight, with our commercial team conducting over 60 meetings and spreading the word about Inaphaea to the wider market.

To discuss any of our updates, please get in touch with Dr Andrew Carnegie, Head of Strategic Commercial Development. 

News round-up: March 2024 

PhD achievement and promotion for Dr Amelia Hatfield 

This month, we were delighted to announce that Inaphaea’s very own Amelia Hatfield passed her PhD viva and has been promoted to the position of Senior Scientist. 
Dr Amelia’s passion for drug discovery began after she obtained her BSc (Hons) Degree in Pharmacology at Nottingham Trent University. Her desire to focus on cancer research led her to pursue an MSc Degree in Oncology at the University of Nottingham, where she conducted her research project in the Children’s Brain Tumour Research Centre (CBTRC).  

Her academic journey continued at the University of Nottingham, where she worked towards her PhD, with a primary research goal of understanding the mechanisms of actions of a set of anti-cancer agents in colorectal cancer, with a specific focus on mutant KRAS. 

Congratulations Amelia! 

Meet the Inaphaea commercial team

Whilst we are led by science here at Inaphaea, we are backed by deep commercial understanding, and appreciate the challenges faced by drug developers. This is thanks to the strength of our commercial team which combines business acumen and experience with scientific expertise. In this blog, we introduce the Inaphaea commercial team and find out what they have to say about the company’s ongoing growth and development. 

BioEurope Spring 

Inaphaea’s Dr Andrew Carnegie and ValiRx’s Mark Treharne were pleased to attend EBD Group’s BioEurope Spring between 18 and 20 March in Barcelona. Supporting One Nucleus’ stand, the team had an incredibly productive time, meeting with delegates in the dedicated one to one sessions and listening to insights from the keynote speakers. 

Partnerships and PDCs  

In the second instalment of our three-part video series, we explore how we work with our expert collaborators. Check it out here. 

We extend our thanks to our collaborators for their input:

  • Dr Gareth Griffiths
  • Steve Trim, CSO at Venomtech Ltd 
  • Professor Claire Thompson, Founder and CEO of Agility Life Sciences 
  • Peter De’Ath, Head of Client Management at HistologiX 
  • Dr Mark Eccleston, Managing Director at OncoLytika
  • Natassja Bush, Managing Director at Inspiralis Limited 

The third and final video of the series explains how our patient-derived cells are used in drug discovery for our clients. Also, you can hear from our collaborators as they share their thoughts on PDCs. Watch the video here

The future of drug discovery 

Drug discovery is known for its high attrition rates that lead to significant investments in both cost and time. But the emergence of patient-derived cells (PDCs) is on track to revolutionise this process, offering a promising route to more efficient and effective drug development. 

In this blog, the Inaphaea team explores the potential of PDCs and their role in shaping the future of drug discovery. Read more. 

Upcoming events 

You can meet the Inaphaea team at the following upcoming events: 

  • The AACR Annual Meeting 2024: 5 – 10 April, San Diego, California 
  • ELRIG’s AI in Drug Discovery Forum: 25 April, Cambridge 
  • Swiss Biotech Day 2024: 22-23 April, Basel, Switzerland  

To arrange a meeting, please email Dr Andrew Carnegie: